GenSight Biologics trades up after €46m Paris IPO

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity IPOs

GenSight Biologics trades up after €46m Paris IPO

Aidan Gregory
July 13, 2016 04:00 pm
pills
colorful pills and tablets on background | DimaSobko/dimasobko - Fotolia

GenSight Biologics, a niche French biotechnology firm focused on treating degenerative retinal and nervous system disorders, has completed its all-primary IPO on Euronext Paris, raising €46m to help bring its flagship drug GS010 to market in Europe and the US.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOsEquityFrance
AG
Aidan Gregory
Gift this article